Revenue Breakdown
Composition ()
No data
Revenue Streams
Journey Medical Corp (DERM) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Qbrexa, accounting for 46.3% of total sales, equivalent to $6.95M. Other significant revenue streams include Accutane and Emrosi. Understanding this composition is critical for investors evaluating how DERM navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Evaluating the bottom line, Journey Medical Corp maintains a gross margin of 61.32%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -8.67%, while the net margin is -13.13%. These profitability ratios, combined with a Return on Equity (ROE) of -47.05%, provide a clear picture of how effectively DERM converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, DERM competes directly with industry leaders such as AARD and LFCR. With a market capitalization of $269.05M, it holds a significant position in the sector. When comparing efficiency, DERM's gross margin of 61.32% stands against AARD's N/A and LFCR's 25.04%. Such benchmarking helps identify whether Journey Medical Corp is trading at a premium or discount relative to its financial performance.
